News on Target Discovery%2C Inc. from BioPortfolio.com http://www.BioPortfolio.com Consolidated Target Discovery%2C Inc. news from BioPortfolio.com Wed, 10 Feb 2010 02:26:06 GMT en Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037759&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037759&THISHREF=http://c.moreover.com/click/here.pl%3fz2537270863%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037759&HITNO=0&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037759&THISHREF=http://c.moreover.com/click/here.pl%3fz2537270863%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037547&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037547&THISHREF=http://c.moreover.com/click/here.pl%3fz2537138965%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037547&HITNO=1&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037547&THISHREF=http://c.moreover.com/click/here.pl%3fz2537138965%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037588&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037588&THISHREF=http://c.moreover.com/click/here.pl%3fz2537162932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037588&HITNO=2&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037588&THISHREF=http://c.moreover.com/click/here.pl%3fz2537162932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037637&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037637&THISHREF=http://c.moreover.com/click/here.pl%3fz2537198799%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037637&HITNO=3&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037637&THISHREF=http://c.moreover.com/click/here.pl%3fz2537198799%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: First call for targets from MRC Centre for Therapeutics Discoveryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035196&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035196&THISHREF=http://c.moreover.com/click/here.pl%3fz2536156074%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035196&HITNO=4&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035196&THISHREF=http://c.moreover.com/click/here.pl%3fz2536156074%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Times: CRT and AstraZeneca form major alliance to create cancer metabolism drugshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033002&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033002&THISHREF=http://c.moreover.com/click/here.pl%3fz2534951817%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033002&HITNO=5&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033002&THISHREF=http://c.moreover.com/click/here.pl%3fz2534951817%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comCancer Research UK: Fragile hope for brain disordershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032818&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032818&THISHREF=http://c.moreover.com/click/here.pl%3fz2534826265%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032818&HITNO=6&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032818&THISHREF=http://c.moreover.com/click/here.pl%3fz2534826265%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDrug Discovery News: Research and Markets: The Contract Research Market for Drug Discovery Technologies: Opportunities for Life Science Suppliershttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032204&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032204&THISHREF=http://c.moreover.com/click/here.pl%3fz2534544615%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032204&HITNO=7&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032204&THISHREF=http://c.moreover.com/click/here.pl%3fz2534544615%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: CRT, AstraZeneca announce alliance to develop new anti-cancer drugshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033316&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033316&THISHREF=http://c.moreover.com/click/here.pl%3fz2535122849%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033316&HITNO=8&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033316&THISHREF=http://c.moreover.com/click/here.pl%3fz2535122849%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: ARCA biopharma, Inc. (formerly ARCA Discovery, Inc.)-Company Report - new market report releasedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036856&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036856&THISHREF=http://c.moreover.com/click/here.pl%3fz2536793458%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036856&HITNO=9&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036856&THISHREF=http://c.moreover.com/click/here.pl%3fz2536793458%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: Sunesis Licenses Drug Discovery Technology To Private Company - Stocks To Watchhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033585&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033585&THISHREF=http://c.moreover.com/click/here.pl%3fz2535279543%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033585&HITNO=10&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033585&THISHREF=http://c.moreover.com/click/here.pl%3fz2535279543%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comQuote.com Japan: Albany Molecular Research Inc. (AMRI) reports 1st Quarter ending March 2010 above estimateshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034006&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034006&THISHREF=http://c.moreover.com/click/here.pl%3fz2535550509%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034006&HITNO=11&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034006&THISHREF=http://c.moreover.com/click/here.pl%3fz2535550509%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarnings Whispers: Infosys Technologies and Elan Pharmaceuticals Apply Co-creation Model to Transform Discovery Research 2/5/10http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036664&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036664&THISHREF=http://c.moreover.com/click/here.pl%3fz2536699449%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036664&HITNO=12&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036664&THISHREF=http://c.moreover.com/click/here.pl%3fz2536699449%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAmerican Pharmaceutical Outsourcing: Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinsons disease biomarkerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034239&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034239&THISHREF=http://c.moreover.com/click/here.pl%3fz2535687055%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034239&HITNO=13&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034239&THISHREF=http://c.moreover.com/click/here.pl%3fz2535687055%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Dishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033208&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033208&THISHREF=http://c.moreover.com/click/here.pl%3fz2535065932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033208&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Target%20Discovery,%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033208&THISHREF=http://c.moreover.com/click/here.pl%3fz2535065932%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: